Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20321105 | 0.84 | MAOA (0.44) | SMN1; SMN2L3MBTL1MEN1KMT2AMAOA | |
| SCHEMBL23804002 | 0.81 | KDM4E (0.39) | ALDH1A1LMNAKDM4EL3MBTL1MAOB | |
| SCHEMBL22374404 | 0.81 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL11912907 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL23804091 | 0.79 | MAOA (0.38) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL3346351 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| Hydrochloric Acid SCHEMBL28530836 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL1232335 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL8926474 | 0.76 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL23804054 | 0.76 | KIF11 (0.39) | SMN1; SMN2MAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2018119395-A1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | ALDH1A1 3706/4885SMN1; SMN2 35/4885LMNA 195/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | ALDH1A1 3706/4885SMN1; SMN2 35/4885LMNA 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.